Clinical Trial Update: Prospective Cohort Study of Neoadjuvant Therapy With Sintilimab (PD-1 Inhibitor) Combined With Chemotherapy in Resectable ESCC

View source ↗

Summary

A prospective cohort study is evaluating neoadjuvant therapy with the PD-1 inhibitor sintilimab plus chemotherapy for resectable esophageal squamous cell carcin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Tyvyt (Sintilimab) (Sintilimab)

Snippet

Sponsor: Tang-Du Hospital | Conditions: Resectable Esophageal Squamous Cell Carcinoma | Status: ENROLLING_BY_INVITATION